BEIJING–(BUSINESS WIRE)–January 16, 2022–
Pharmaron Beijing Co., Limited (stock code: 300759.SZ/3759.HK) (“Pharmaron”) today announced the appointment of Dr. Antony (Tony) Davies as Senior Vice President, UK CMC, effective dated 10 January 2022. The UK Chemistry, Manufacturing and Control (CMC) business comprises operations in Hoddesdon and Cramlington, UK.
Tony has served as Senior Vice President, Process R&D, since 2019, having been promoted to Vice President, Process Chemistry, a position he has held since Pharmaron acquired the MSD Hoddesdon site in 2016. Previously, he was Director of Process Chemistry at MSD where he had worked for 25 years. Tony got his Ph.D. degree in organic chemistry from the University of East Anglia and his MBA from Cass Business School.
CMC’s UK business currently includes operations in Hoddesdon and Cramlington, UK. The Hoddesdon site offers discovery services, process development, early-stage cGMP API manufacturing, formulation development and GMP pharmaceutical manufacturing. The Cramlington site, acquired by Pharmaron on January 10, 2022 from Recipharm, offers cGMP manufacturing services ranging from pilot scale to commercial metric ton scale.
The expansion of Pharmaron’s world-class chemistry and manufacturing portfolio is an important part of its fully integrated platform. Given Tony’s success as head of the Hoddesdon site, he has been appointed to oversee CMC’s UK business, which includes the integration of the Cramlington site.
Tony reports directly to Pharmaron’s Chairman and CEO, Dr Boliang Lou.
About Pharmaron
Pharmaron (stock code: 300759.SZ/3759.HK) is a leading provider of R&D services to the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities and established a wide range of research, development and manufacturing service capabilities throughout the process of drug discovery, preclinical and clinical development across multiple therapeutic modalities, including small molecules, biologics and CGT products. . With over 15,000 employees and operations in China, the United States and the United Kingdom, Pharmaron has an excellent track record of providing R&D solutions to its partners in North America, Europe, Japan and China. www.pharmaron.com
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220116005033/en/
CONTACT: For more information, please contact:
Ellen Cabral (Media) Tel. : +1 617 901 2216,ellen.cabral@pharmaron.com
KEYWORD: IRELAND CHINA UNITED STATES UNITED KINGDOM NORTH AMERICA ASIA PACIFIC EUROPE
KEYWORD INDUSTRY: SCIENCE OTHER SCIENCES BIOTECHNOLOGY PHARMACEUTICAL RESEARCH GENERAL HEALTH HEALTH CLINICAL TRIALS
SOURCE: Pharmaron Beijing Co., Limited
Copyright BusinessWire 2022.
PUBLISHED: 01/16/2022 7:00 PM / DISK: 01/16/2022 7:02 PM
Copyright BusinessWire 2022.
